Global Vaccine Adjuvants Market Size was valued nearly USD 467 million by 2016 and is estimated to reach up to USD xx.xx million by 2025. According to latest study conducted by our analysts and industry experts, the global market is expected to grow at a CAGR of 10.21% during the forecast period that is 2017-2025. North America is anticipated to hold the prime market share in 2017, followed by Europe.  

Global Market Growth Opportunities (Revenue, Growth) By 2017-2025

Adjuvants are the substances, which are added to vaccines for increasing the human body's response of immunity to the vaccine. The vaccine adjuvants are mandatorily tested for safety in clinical trials by various organizations such as FDA before their licensing procedure for the patient’s use. Vaccine adjuvants market is projected to grow over a significant growth rate in the projected period, owing to increasing incidences of several chronic diseases such as diabetes, cancer, arthritis, etc., coupled with increasing awareness towards regarding these diseases in both developed and developing nations.

Market Dynamics

Rising incidences of infectious diseases such as HIV, Human Papillomavirus (HPV), tuberculosis, etc., along with cervical cancer and other diseases is anticipated to boost the vaccine adjuvants market over the projected period. Moreover, increasing focus on the long-lasting immunization against all kinds of diseases including existing and emerging is further expected to boost the market. The research & development on the vaccine adjuvants is increasing significantly, owing to the inadequate immunogenicity of various vaccine antigens. Additionally, increasing use of synthetic and recombinant vaccines is further expected to fuel the market growth over the coming years.

Several prominent players in this market are continuously engaged in the development and discovery of many new adjuvants to use in the treatment of fatal diseases such as chronic illnesses, arthritis, etc. There are various vaccine adjuvants, which are under clinical trials. Some of them are ISCOM & ISCOMMATRIX, AS02, and AS01. The presence of these drugs in the pipeline is further estimated to accelerate the vaccine adjuvants market over the forecast period.

The market is expected to restrain by the increasing costs of immunization in the developed and as well as developing economies. Moreover, there is a lack of developed healthcare facilities in the developing economies of Asia Pacific. This will act as a significant restraint to the growth of vaccine adjuvants market over the coming years.

By Product Type Insights: By product type, the vaccine adjuvants market has been segmented into particulate, emulsions, pathogens, and others which include combinations, etc. Among these, particulate-type is expected to hold the prime market share, followed by emulsions. This is majorly attributed by the increasing presence of multiple vaccine adjuvants, as they offer greater efficiency against several chronic diseases.

Pathogens product segment is anticipated to grow at a leading CAGR over the projected period. The need for pathogens is increasing significantly over the forecast period, majorly owing to the increasing product use in treating various diseases such as HPV, tuberculosis, etc. Some of the recent pathogenic vaccine adjuvants tested are monophosphoryl lipid A. This is further combined with alum, which helps in the production of AS04 adjuvant used in HPV-Cervarix.

Region Analysis

The global vaccine adjuvants market is divided into regions that are North America - U.S, Canada, Other; Asia-Pacific -India, Japan, China, Australia, Other; Europe - UK, Russia, France, Brazil, Other; Middle East and Africa. Every region analysis details in sense of growth, revenue, volume, challenges, and opportunities with the regional and global key players. North America is anticipated to hold the prime market share in 2017, followed by Europe. Key factors contributing to the growth of the market include increasing R&D investments for the development of many new therapeutics, coupled with increasing fatal epidemic diseases such as polio, AIDS, malaria, cholera, etc. This is leading to the growth in the need for immunization against acute and chronic diseases. Moreover, the presence of regional key market players in the U.S. will further increase the penetration of the product. For instance, Adjuvance Technologies, Inc. developed a adjuvants product portfolio, which is targeted to treat various diseases.

Global Vaccine Adjuvants Market Size, Share Analysis By Region 2017

The Asia Pacific is predicted to grow at a prime growth rate, due to the continuous development of healthcare facilities in the developing countries such as China, India, South Korea, etc., coupled with growing availability of medicines, and rising R&D investments to meet the unmet product demands. Middle East and Africa held the measurable growth in the global market in 2018 and will expand at the significant CAGR during the forecast years.    

Global Vaccine Adjuvants Market Study Objective

1. To forecast the market size of vaccine adjuvants market, along with describing and defining the market, in terms of volume and revenue as well as market opportunities for stakeholders, in order to provide a competitive landscape for global market players.

2. Market analysis and forecast of vaccine adjuvants market on the basis of region, substrate and application or end-use industry. To profile major market players, and to analyze their market shares and essential competencies comprehensively.

3. To analyze and elaborate significant factors that will have major impact on the growth of vaccine adjuvants market, such as drivers, restraints, challenges and opportunities.

4. Regional analysis of vaccine adjuvants market, to induce market size of five global major regions, which include, Europe, North America, South America, Middle East & Africa and Asia Pacific.

5. Strategic analysis of micromarkets, in terms of individual prospects, opportunities, growth trends and their involvement in overall market.

6. To provide detailed analysis of competitive and strategic developments in the vaccine adjuvants market like new product launch, partnership & agreement, investment & expansion, and company merger & acquisitions.

Competitive Landscape Insights

Some of the potential participants in the global vaccine adjuvants market include Novavax, Inc., GlaxoSmithKline plc., SPI Pharma, Adjuvance Technologies, Inc., CSL Limited; Agenus, Inc., Brenntag Biosector, and InvivoGen among several others. Key players in this market are focusing more on the expansion of their businesses mostly in developing countries to increase their geographical reach. Moreover, they are adopting several strategies such as mergers & acquisitions, collaborations, and also investing in the development of new products. This will enhance their product portfolio, and also help them to improve their market position. For instance, GSK collaborated with a company named Exscientia for the development of new drugs, in July 2017.

Global Vaccine Adjuvants Market Study Report Offer You!

The global market study report gives an idea about market size, share, stock, equity, investment and total price analysis. Also, the report provides comprehensively industry insights with all major factors such as market credit, allocation, demand, distribution, market scope, key players, end user & applications, provisions, livestock, commodities and industry economics analysis, future growth & forecast. The global market report includes all depth data like pre-market emphasis, market survey, market investment, industry advice, portfolio, finance, access, trade, market exploration, industry review and market predication & projection to develop effective strategies for optimizing their market position.